Interferons in relapsing remitting multiple sclerosis.

Interferons in relapsing remitting multiple sclerosis.

Bibliográfalaš dieđut
Váldodahkki:	Goodin, D
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2003

Geahča maid

Interferons in relapsing remitting multiple sclerosis - Authors' reply
Dahkki: Filippini, G, et al.
Almmustuhtton: (2003)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
Dahkki: Filippini, G, et al.
Almmustuhtton: (2003)

Interferons in relapsing remitting multiple sclerosis: a systematic review.
Dahkki: Filippini, G, et al.
Almmustuhtton: (2003)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
Dahkki: Dian HE, et al.
Almmustuhtton: (2014-09-01)

Erratum to Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
Dahkki: Dian HE
Almmustuhtton: (2015-01-01)

Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
Dahkki: Làzaro Aurelio Vàzquez Gòmez, et al.
Almmustuhtton: (2022-10-01)

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.
Dahkki: Wylezinska, M, et al.
Almmustuhtton: (2003)

Thalamic neurodegeneration in relapsing: Remitting multiple sclerosis
Dahkki: Cifelli, A, et al.
Almmustuhtton: (2003)

Comorbidity in in patients with relapsing-remitting multiple sclerosis
Dahkki: O.V. Somilo, et al.
Almmustuhtton: (2024-10-01)

Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
Dahkki: Burcu Altunrende, et al.
Almmustuhtton: (2017-12-01)

Advances in the treatment of relapsing - Remitting multiple sclerosis
Dahkki: Radu Tanasescu, et al.
Almmustuhtton: (2014-04-01)

Postural Control in Relapsing-Remitting Multiple Sclerosis
Dahkki: Flavia Salvaterra Cusin, et al.
Almmustuhtton: (2022-10-01)

Direct costs of relapses in patients with relapsing-remitting multiple sclerosis
Dahkki: V. Casado, et al.
Almmustuhtton: (2021-07-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
Dahkki: Petkau, A, et al.
Almmustuhtton: (2004)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
Dahkki: Petkau, A, et al.
Almmustuhtton: (2004)

Cost-utility analysis of interferon beta-1a (Avonex and Cinnovex) for relapsing remitting multiple sclerosis
Dahkki: Rahil Sadat Shahtaheri, et al.
Almmustuhtton: (2018-06-01)

Experience with the long-term use of interferons β in the treatment of relapsing-remitting multiple sclerosis. Case report
Dahkki: Taras O. Simaniv, et al.
Almmustuhtton: (2024-12-01)

Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
Dahkki: Fernando Rodríguez-Jorge, et al.
Almmustuhtton: (2024-11-01)

Oxidative stress in relapsing-remitting multiple sclerosis patients
Dahkki: Samaneh Sabouri, et al.
Almmustuhtton: (2023-09-01)

Effectiveness of Copaxone in patients with relapsing-remitting multiple sclerosis
Dahkki: V. M. Alifirova, et al.
Almmustuhtton: (2010-08-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
Dahkki: Halil Önder
Almmustuhtton: (2019-06-01)

Serum prolactin in patients with relapsing remitting multiple sclerosis
Dahkki: Hoda A. Alwakil, et al.
Almmustuhtton: (2020-07-01)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
Dahkki: Burgal María, et al.
Almmustuhtton: (2010-04-01)

Mild cognitive impairment in relapsing-remitting multiple sclerosis
Dahkki: Dimakopoulou Aikaterini, et al.
Almmustuhtton: (2008-04-01)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
Dahkki: Damiano Paolicelli, et al.
Almmustuhtton: (2016-01-01)

Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing–Remitting-Multiple Sclerosis Patients
Dahkki: Chiara D’Angelo, et al.
Almmustuhtton: (2018-06-01)

Cerebellar information processing in relapsing-remitting multiple sclerosis (RRMS).
Dahkki: Lesage, E, et al.
Almmustuhtton: (2010)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
Dahkki: E. Lesage, et al.
Almmustuhtton: (2010-01-01)

Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines
Dahkki: Paty, D, et al.
Almmustuhtton: (1999)

Subtypes of relapsing-remitting multiple sclerosis identified by network analysis
Dahkki: Quentin Howlett-Prieto, et al.
Almmustuhtton: (2023-01-01)

Altered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis
Dahkki: Forooz Peiravian, et al.
Almmustuhtton: (2016-09-01)

Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
Dahkki: Fernando Rodríguez-Jorge, et al.
Almmustuhtton: (2024-12-01)

Prooxidant-antioxidant balance in relapsing-remitting multiple sclerosis patients
Dahkki: Samaneh Sabouri, et al.
Almmustuhtton: (2023-07-01)

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
Dahkki: Sainz de la Maza S, et al.
Almmustuhtton: (2023-06-01)

Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
Dahkki: Roberto Bomprezzi
Almmustuhtton: (2015-01-01)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
Dahkki: Romme Christensen Jeppe, et al.
Almmustuhtton: (2012-09-01)

The condition of the cardiovascular system in patients with relapsing-remitting multiple sclerosis
Dahkki: O. A. Traktirskaya, et al.
Almmustuhtton: (2019-03-01)

Efficacy and Safety of PEGylated Interferons for Relapsing-Remitting Multiple Sclerosis in Adult Patients: Results of Matching-Adjusted Indirect Comparison
Dahkki: Taras O. Simaniv, et al.
Almmustuhtton: (2024-04-01)

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Dahkki: Ebers, G, et al.
Almmustuhtton: (1998)

Comparison Of The Expression Of MiR-326 Between Interferon Beta Responders And Non-Responders In Relapsing-Remitting Multiple Sclerosis
Dahkki: Mahtab Fattahi, et al.
Almmustuhtton: (2020-04-01)